The purpose of this study is to determine whether Adductor-Canal-Blockade (ACB) is superior to placebo when it comes to analgetic efficacy in high pain responders after Total Knee Arthroplasty (TKA). High pain responders are defined as patients reporting VAS \> 60 during knee flexion the 1. or 2. day after surgery.
The patients will be included the 1. or 2. day after surgery. All TKA patients will be screened. Those reporting VAS \> 60 during active 45 degrees knee flexion will be asked to participate. Included patients will receive 2xACB (singleshot) first placebo (30ml saline) and then ropivacaine (30ml ropivacaine 7,5mg/ml) or the other way around (randomized). There will be 45 minutes between the two blockades. The blockades will be ultrasound guided.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
50
Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml). Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine.
please see intervention description for ropivacaine
Gentofte Hospital
Copenhagen, Denmark
Difference in VAS between ACB and placebo during active 45 degrees knee flexion
Time frame: 45 minutes
Difference in mean VAS between the groups during active knee flexion
Time frame: 15, 30, 60, 75 and 90 minutes
Difference in mean VAS between the groups at rest
Time frame: 15, 30, 60, 75 and 90 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.